BioSight
Companies
enGene Therapeutics Inc. logo

ENGN

NASDAQSAINT-LAURENT
enGene Therapeutics Inc.

enGene Therapeutics is a clinical-stage biotech company developing detalimogene voraplasmid, an immunotherapy candidate. enGene is pursuing regulatory approval from the FDA and EMA, with ongoing and planned clinical trials designed to support potential marketing authorization. The company is focused on advancing detalimogene through late-stage and pivotal clinical development toward commercialization.

Price history not yet available for ENGN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar